探讨溃疡性结肠炎患者联用美沙拉嗪与枯草杆菌二联的治疗效果

To Investigate the Therapeutic Effect of Mesalazine Combined with Bacillus Subtilis in Patients with Ulcerative Colitis

目的:探讨溃疡性结肠炎(UC)患者联用美沙拉嗪与枯草杆菌二联治疗的临床疗效。方法:将90例UC患者确定为本研究的观察对象,按照随机的分组方法,将其分为各有45例患者的研究组和对照组。对照组服用美沙拉嗪治疗,研究组联用美沙拉嗪与枯草杆菌二联活菌治疗,对两组的临床总有效率进行评价,比较Mayo指数、免疫功能指标治疗前后的组间变化,记录治疗期间药物不良反应发生情况。结果:研究组的总有效率与对照组的比较,显著提高(93.33%VS75.56%,P<0.05)。Mayo指数经过治疗后,两组均下降(P<0.05),且研究组治疗后Mayo指数较对照组降低(P<0.05)。CD4^(+)、CD4^(+)/CD8^(+)水平经过治疗后均升高,CD8^(+)水平经过治疗后均下降(P<0.05);治疗后,研究组CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组(P<0.05)。研究组治疗期间药物不良反应发生率较对照组降低(P<0.05)。结论:UC患者联用美沙拉嗪与枯草杆菌二联活菌治疗可以减轻患者临床症状,提高患者的免疫功能,取得的治疗效果确切,且药物安全性较好,可以在临床进行大力推广。

Objective:To investigate the clinical efficacy of mesalazine combined with Bacillus subtilis in the treatment of ulcerative colitis(UC).Method:90 patients with UC were selected as the subjects of this study.According to the random grouping method,they were divided into the study group and the control group with 45 patients each.The control group was treated with mesalazine,and the study group was treated with mesalazine and Bacillus subtilis.The total clinical effective rates of the two groups were evaluated,and the changes of Mayo index and immune function indexes before and after treatment were compared.The occurrence of adverse drug reactions during the treatment period was recorded.Result:The total effective rate of the study group was significantly higher than that of the control group(93.33%VS 75.56%,P<0.05).After treatment,the Mayo index decreased in both groups(P<0.05),and the Mayo index in the study group was lower than that in the control group(P<0.05).The levels of CD4^(+)and CD4^(+)/CD8^(+)increased after treatment,and the levels of CD8^(+)decreased after treatment(P<0.05);After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group(P<0.05).The incidence of adverse drug reactions in the study group was lower than that in the control group(P<0.05).Conclusion:The combination of mesalazine and Bacillus subtilis in the treatment of UC patients can reduce the clinical symptoms and improve the immune function of patients.The treatment effect is accurate,and the drug safety is good,which can be vigorously promoted in clinical practice.